Home / News / BioBlast®

EXPLORE OUR

BioBlast®

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast™ updates below.
Scientific Name: bevacizumab

2022

EU | CHMP recommends approval of Celltrion’s Vegzelma® (bevacizumab/biosimilar to Avastin®)

June 23, 2022

The CHMP recommended the approval of Celltrion’s Vegzelma® (bevacizumab/biosimilar to Avastin®) for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

ID | Innovent’s Bevagen® approved in Indonesia

June 13, 2022

Innovent Biologics and PT Etana Biotechnologies announced that the Indonesian Food and Drugs Authority has approved Bevagen® (bevacizumab biosimilar) for metastatic colorectal cancer (mCRC); locally recurrent or metastatic triple negative breast cancer (mTNBC); advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC); epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC); and cervical cancer (CC).  According to Innovent and Etana, Bevagen® may be “the first Chinese antibody drug to be marketed and locally produced in Southeast Asia”.

US | Outlook Therapeutics voluntarily withdraws its BLA for ONS-5010/LYTENAVA™ (bevacizumab)

May 31, 2022

Outlook Therapeutics announced that it has voluntarily withdrawn its BLA for ONS-5010/LYTENAVA™ (proposed biosimilar bevacizumab) after the FDA requested additional information.  Outlook Therapeutics announced that it is actively working to respond to the FDA’s request and plans to re-submit a revised BLA by September 2022.

CA | Viatris launches Abevmy® (biosimilar bevacizumab) in Canada

May 19, 2022

Biocon Biologics and Viatris announce the launch of Abevmy® (biosimilar bevacizumab) in Canada.  Abevmy® was jointly developed by Biocon and Viatris, and is indicated for metastatic colorectal cancer, locally advanced, metastatic or recurrent non-small cell lung cancer, platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer and malignant glioma-glioblastoma.  This is the fourth Canadian biosimilar launched by Viatris.

Under the portfolio development agreement (which includes a “broad portfolio of biosimilars and insulin analogs”), Viatris has exclusive commercialisation rights in the U.S., Canada, Australia, New Zealand, EU and the European Free Trade Association countries, whilst Biocon has them in certain emerging markets.  They share co-exclusive commercialisation rights in the rest of the world.

Celltrion releases the results of Ph III trials of CT-P16 (biosimilar bevacizumab candidate)

April 13, 2022

Korea Biomedical Review reported that Celltrion released the results of its Ph III trials of CT-P16 (biosimilar bevacizumab candidate) at the American Association for Cancer Research 2022.  Celltrion said that CT-P16 demonstrated equivalence in efficacy with Avastin®.  Based on these results, Celltrion has completed an application for CT-P16 product approval in Korea, the U.S., and the EU seeking approval for a full label.

FDA approves Amneal’s BLA for Alymsys® (biosimilar bevacizumab)

April 13, 2022

Amneal Pharmaceuticals announced that the FDA has approved its BLA for Alymsys® (biosimilar bevacizumab) marking the second of three oncology biosimilar approvals Amneal expects to receive in 2022.  Alymsys® was developed by mAbxience, and its approval is the third biosimilar bevacizumab approved in the US.

FDA approves Amneal’s Releuko™ (biosimilar filgrastim)

March 1, 2022

Amneal announced that the FDA has approved Amneal’s first biosimilar product Releuko™ (biosimilar filgrastim), a product developed by Kashiv Speciality Pharmaceuticals (which was acquired by Amneal in April 2021).  Amneal also disclosed that US applications for biosimilar pegfilgrastim and bevacizumab are under FDA review, and Amneal plans to launch both products in 2022.

Samsung Bioepis secured 10 biosimilar products on its 10th year anniversary

February 28, 2022

The Korea Herald reported that Samsung Bioepis has secured a total of 10 biosimilar products on its 10th year anniversary.  Six biosimilars have been approved globally: infliximab, etanercept, adalimumab, trastuzumab, bevacizumab and ranibizumab.  Eculizumab has recently completed its Ph III clinical trial, and three other biosimilar candidates are under Ph III trials.

US | New real-world study of Pfizer’s Zirabev® (biosimilar bevacizumab)

February 10, 2022

A real-world study of Pfizer’s Zirabev® (biosimilar bevacizumab) indicates that Zirabev® has been well adopted in US oncology practice.

Innovent and Eli Lilly announce the results of Ph Ib trials of Tyvyt® (sintilimab) plus biosimilar bevacizumab for advanced hepatocellular carcinoma

January 21, 2022

Innovent and Eli Lilly announced the results of Phase Ib trials of Tyvyt® (sintilimab) plus biosimilar bevacizumab for advanced hepatocellular carcinoma.  Innovent says that the safety profile is consistent with that observed in previously reported studies, without new or unexpected safety signals.

Amneal to acquire Saol’s Baclofen franchise

January 5, 2022

Amneal Pharmaceuticals and Saol Therapeutics announced that Amneal will acquire Saol’s Baclofen franchise.  This acquisition is expected to bolster Amneal’s commercial infrastructure in advance of its planned launches of biosimilar filgrastim, biosimilar pegfilgrastim and biosimilar bevacizumab in 2022.

2021

CN | China’s NMPA accepts Innovent’s supplemental New Drug Application for sintilimab plus biosimilar bevacizumab

December 24, 2021

Innovent Biologics announced that China’s NMPA has accepted the supplemental New Drug Application for sintilimab plus biosimilar bevacizumab injection and chemotherapy in patients with EGFR-mutated non-squamous non-small cell lung-cancer who progressed after EGFR-TKI therapy.

CN | China’s NMPA approves Hanbeitai® (biosimilar bevacizumab)

December 3, 2021

Shanghai Henlius Biotech announced that China’s NMPA has approved Hanbeitai® (biosimilar bevacizumab) for the treatment of metastatic colorectal cancer and unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer.

CN | NMPA approves Pusintin® (biosimilar bevacizumab)

December 1, 2021

Tot Biopharm announced that China’s NMPA has approved Pusintin® (biosimilar bevacizumab) for the treatment of patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer and patients with metastatic colorectal cancer.

Innovent releases the results of Ph III studies of sintilimab and BYVASDA® (bevacizumab biosimilar) combined with chemotherapy in lung cancer

November 21, 2021

Innovent released the results of a Ph III study of sintilimab and BYVASDA® (bevacizumab biosimilar) combined with chemotherapy in patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed after EGFT-TKI therapy.

Celltrion provides update on biosimilars pipeline

November 10, 2021

Celltrion announced its Q3 2021 financial results. Celltrion reported that Remsima® (infliximab biosimilar) has obtained a 53% market share in Europe and 21% market share in Japan. Celltrion reported that Truxima® (rituximab biosimilar) has obtained a 40% market share in Europe and Herzuma® (trastuzumab biosimilar) has obtained a 14% market share in Europe. Celltrion also reported that it expects to launch biosimilar bevacizumab in 2022, biosimilar ustekinumab in 2023, biosimilar omalizumab and aflibercept in 2024 and biosimilar denosumab in 2025.

EU | Celltrion submits MAA to EMA for biosimilar bevacizumab

October 12, 2021

The Korea Herald announced that Celltrion has submitted a Marketing Authorisation Application to the EMA for CT-P16 (proposed bevacizumab biosimilar).

New study reports on Boan Biotechnology’s LY01008 (proposed bevacizumab biosimilar)

October 2, 2021

A new study published in Cancer Communications reported that Boan Biotechnology’s LY01008 (proposed bevacizumab biosimilar) demonstrated similarity to Avastin® in patients with advanced or recurrent non-squamous NSCLC.

KR | US | Celltrion submits application for CT-P16 (proposed biosimilar bevacizumab) in the US and Korea

October 1, 2021

Korea Biomedical Review reported that Celltrion has submitted an application for CT-P16 (proposed biosimilar bevacizumab) in the US and Korea.

CA | Health Canada has approved Bambevi® (biosimilar bevacizumab)

September 27, 2021

Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer.

Henlius to present new studies on serplulimab (anti-PD-1 mAb) and HLX04 (bevacizumab biosimilar)

September 18, 2021

Henlius announced that it will present the results of new studies on serplulimab (anti-PD-1 mAb) and HLX04 (bevacizumab biosimilar) at the 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO).

CA | EU | US | Bio-Thera Solutions and Sandoz enter into agreement for bevacizumab biosimilar

September 8, 2021

Bio-Thera Solutions announced that it has entered into a commercialisation and license agreement with Sandoz to commercialise BAT1706 (proposed bevacizumab biosimilar). Under the agreement, Sandoz will commercialise the product in the US, Europe, Canada and other international markets in exchange for an upfront payment, potential milestone payments and royalties on product sales.

AU | Australia’s TGA approves Mylan/Alphapharm’s Abevmy® (biosimilar bevacizumab)

September 6, 2021

Australia’s TGA approved Mylan/Alphapharm’s Abevmy® (biosimilar bevacizumab) for the treatment of colorectal cancer, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube, peritoneal cancer and cervical cancer.

Outlook Therapeutics reports positive data from Ph III trials of bevacizumab biosimilar

August 3, 2021

Outlook Therapeutics reported positive efficacy and safety data from Ph III trials of ONS-5010 (proposed bevacizumab biosimilar) for the treatment of neovascular age-related macular degeneration.

Amgen released its Q2 2021 financial results

August 3, 2021

Amgen released its Q2 2021 financial results, reporting double digit volume growth for Prolia® (denosumab), Repatha® (evolocumab), Mvasi® (biosimilar bevacizumab) and Kanjinti® (biosimilar trastuzumab).

American Academy of Ophthalmology pushed back against pressure to use bevacizumab biosimilars off-label

July 29, 2021

The American Academy of Ophthalmology pushed back against insurance company pressure to use new bevacizumab biosimilars off-label in eye treatment as alternatives to Avastin® (bevacizumab) in the absence of supporting studies.

Shanghai Henlius Biotech doses first patient in Ph I bevacizumab trials

July 19, 2021

Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of HLX04-O (proposed bevacizumab biosimilar) in the treatment of wet age-related macular degeneration.

AU | AU’s PBAC recommends listing Mvasi, Keytruda and Stelara

July 6, 2021

Australia’s PBAC recommended the listing of Amgen’s Mvasi® (biosimilar bevacizumab). The PBAC also recommended listing Keytruda® (pembrolizumab) for the first line treatment of unresectable or metastatic mismatch repair deficient colorectal cancer and recommended listing Stelara® (ustekinumab) for the treatment of paediatric patients with severe chronic plaque psoriasis.

New data on Luye Pharmaceuticals’ proposed bevacizumab biosimilar published

June 29, 2021

A new study published in Cancer Communications concluded that Luye Pharmaceuticals’ LY01008 (proposed bevacizumab biosimilar) demonstrated similarity to reference Avastin® in terms of efficacy and safety in patients with advanced or recurrent non-squamous non-small cell lung cancer

CN | NMPA approves sNDA for Tyvyt® (sintilimab) in combination with Byvasda® (biosimilar bevacizumab)

June 27, 2021

Innovent Biologics announced China’s National Medical Products Administration has approved its supplemental New Drug Application for Tyvyt® (sintilimab) in combination with Byvasda® (biosimilar bevacizumab) as a first-line treatment for people with advanced or unresectable hepatocellular carcinoma.

US | FDA accepts BLA for Amneal’s proposed bevacizumab biosimilar

June 17, 2021

Amneal announced the FDA has accepted the BLA for Alymsys™ (proposed bevacizumab biosimilar). Alymsys™ was developed in collaboration with mAbxience.

Celltrion reports Q1 2021 financial results

May 12, 2021

Celltrion released its Q1 2020 financial results, reporting that YoY sales of Celltrion biosimilars increased by 23%.  Celltrion announced that it is planning to complete Ph III trials of biosimilar bevacizumab in the first half of 2021, and that ustekinumab, aflibercept, omalizumab and denosumab candidates remain in Ph III trials.

Merck reports its vision for Organon

May 3, 2021

Merck reported the vision, focus and business model for its new standalone company, Organon.  Merck disclosed that Organon with have a direct sales presence in 58 markets, with key growth drivers in Organon’s biosimilars portfolio expected to be Renflexis® (biosimilar infliximab), Aybintio® (biosimilar bevacizumab) and Hadlima® (biosimilar adalimumab).

EU | Biocon receives EC authorisation for Abevmy® (biosimilar bevacizumab)

April 27, 2021

Biocon announced it has received EC marketing authorisation for Abevmy® (biosimilar bevacizumab).  This follows the positive recommendation made by the CHMP for Abevmy® on 01 March 2021.

AU | PBAC publishes March outcomes

April 26, 2021

Australia’s PBAC published the outcomes of its March 2021 meeting. The recommendations include:

  • Mvasi® (Amgen’s biosimilar bevacizumab): the PBS listing has been changed to an unrestricted benefit to allow access to combination treatment with atezolizumab.
  • Beovu® (brolucizumab): Beovu® was recommended for subfoveal choroidal neovascularisation due to AMD.
  • Keytruda® (pembrolizumab): PBAC recommended Section 100 Authority Required listing for the treatment of metastatic colorectal cancer.

Roche published Q1 2021 earnings report

April 21, 2021

Roche published its Q1 2021 earnings report, noting significant impacts from biosimilars. In particular, Roche attributed a combined sales reduction of CHF 1.6 billion to the impact of rituximab, bevacizumab and trastuzumab biosimilars.

CN | NMPA accepts Luye Pharma’s bevacizumab application

April 20, 2021

Luye Pharma announced its marketing authorisation application for LY01008 (proposed bevacizumab biosimilar) has been accepted by China’s National Medical Products Administration.

RU | Prestige Biopharma and Pharmapark reach biosimilar bevacizumab deal

April 15, 2021

Prestige Biopharma and Pharmapark announced they have reached an agreement for the commercialisation of Prestige Biopharma’s proposed bevacizumab biosimilar in the Russian Federation.

EU | STADA launches Oyavas® (biosimilar bevacizumab) in the Netherlands and Germany

March 30, 2021

STADA launched Oyavas® (biosimilar bevacizumab) in the Netherlands and Germany. Oyavas® is indicated for carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

EU | CHMP recommends listing Biocon’s Abevmy®(biosimilar bevacizumab)

March 1, 2021

Biocon and Viatris announced that the CHMP has adopted a positive opinion recommending the marking authorisation of Abevmy® (biosimilar bevacizumab). If approved, Abevmy® will be available for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer in 100mg and 400mg injections. The decision of the EC is expected in May 2021.

Roche reports huge erosion of YoY CER growth in key areas

February 4, 2021

Roche reports a huge erosion of its year on year CER growth in key areas, attributing this decline to COVID-19 impacts and biosimilars. Roche reported the YoY CER growth of Avastin (bevacizumab) was -25%, with the hematology franchise (including rituximab) at -22% and HER2 franchise (including trastuzumab and pertuzumab) at -8%.

EU | CHMP recommends 13 medicines for approval

January 29, 2021

The CHMP recommends13 medicines for approval. Among the recommendations were two bevacizumab biosimilars, Mabxience’s Alymsys® and STADA’s Oyavas®.

US | FDA accepts BLA for Bio-Thera’s biosimilar bevacizumab

January 28, 2021
Bio-Thera Solutions announces the FDA has accepted its BLA for BAT1706 (proposed bevacizumab biosimilar).

Innovent signs bevacizumab deal

January 18, 2021

Innovent announces it has signed a licensing agreement with PT Etana Biotechnologies for Byvasda® (biosimilar bevacizumab). Under the agreement, Etana will receive commercialisation rights in Indonesia in exchange for milestone payments and double-digit royalties on net sales.

2020

CN | Innovent receives additional indication in China

December 27, 2020
Innovent announced China’s NMPA has approved Byvasda® (biosimilar bevacizumab) for the additional indication of adult recurrent glioblastoma.

FDA defers action on Biocon’s bevacizumab biosim

December 25, 2020
Biocon announces that it has been informed by the FDA of a deferred action on the BLA for its proposed bevacizumab biosimilar. This deferral was attributed to COVID-19, as the FDA was unable to conduct the required inspection of the manufacturing facility. Biocon is now awaiting dates for the inspection to occur.

BR | Bio-Thera Solutions licenses bevacizumab biosim in Brazil

December 21, 2020
Bio-Thera Solutions announces it has reached a licensing agreement with Biomm SA for BAT1706 (proposed bevacizumab biosimilar). Under the agreement, Biomm will have exclusive rights to distribute and market the drug in Brazil. Bio-Thera has filed license applications for BAT1706 in the US, EU and China.

EU | Bio-Thera submits EU MA for bevacizumab

November 26, 2020

Bio-Thera Solutions announced it has submitted a marketing authorisation application for BAT1706 (proposed bevacizumab biosimilar) in EU.

Innovent releases Ph III sintilimab and bevacizumab results

November 22, 2020

Innovent releases results of Ph III trials of Tyvyt® (sintilimab) with Byvasda® (biosimilar bevacizumab) as first-line treatment in patients with Advanced Hepatocellular Carcinoma (HCC).

Shanghai Henlius Biotech reports on Ph III bevacizumab trials

November 20, 2020
Shanghai Henlius Biotech reports positive results from Ph III trials of its biosimilar bevacizumab candidate.

US | Genentech sues Centus over bevacizumab biosimilar

November 15, 2020
Genentech files a complaint against Centus Biotherapeutics, Fujifilm Kyowa Kirin Biologics, Fujifilm Corp and Kyowa Kirin relating to its proposed bevacizumab biosimilar. Genentech asserts that Centus failed to provide sufficient information for Genentech to complete an analysis of potential patent infringements.

 

EU | CHMP adopts positive opinion for Samsung Bioepis’ bevacizumab

November 12, 2020

The CHMP adopts a positive opinion for the marketing approval for Samsung Bioepis’ Onbevzi® (biosimilar bevacizumab). Onbevzi® will be available as a 25mg/mL concentrate for solution for infusion, and is indicated for the treatment of carcinoma or the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

All | Henlius and Essex enter co-development and exclusive license agreement for HLX04

October 15, 2020

Henlius and Essex announce they have entered into a co-development and exclusive license agreement for HLX04 (proposed bevacizumab biosimilar). Under the agreement, Essex will be granted an exclusive license to develop, manufacture and commercialise HLX04 globally. Essex will be responsible for 80% of the costs and expenses in relation to the development of HLX04. Henlius is entitled to milestone payments of up to US$43 million, as well as royalties of up to 10% of annual net sales of the product.

EU | Centus Biotherapeutics announces EC marketing authorisation for Equidacent®

September 29, 2020

Centus Biotherapeutics announces it has received EC marketing authorisation for Equidacent® (biosimilar bevacizumab). Equidacent® has been exclusively licensed to Fujifilm Kyowa Kirin Biologics on a worldwide basis.

Innovent announces Ph III trial update

September 28, 2020

Innovent announces its ph III trial of Byvasda® (proposed bevacizumab biosimilar) in combination with Tyvyt® (sintilimab) met its primary endpoints of progression-free survival and overall survival. Innovent reported that the safety profile of both products was consistent with previously reported studies, and no new safety signals were identified.

The Centre for Biosimilars reports data demonstrates positive findings for Ph I trials of HD201

September 17, 2020

The Centre for Biosimilars reports that data presented at the ESMO Virtual Congress by PrestigeBiopharma demonstrates positive findings for Ph I trials of HD201 (proposed bevacizumab biosimilar). HD201 is current under review by the EMA.

Targeted Oncology reports results of Ph III trial of Samsung Bioepis’ SB8

September 3, 2020

Targeted Oncology reports the results of a Ph III trial of Samsung Bioepis’ proposed bevacizumab biosimilar, SB8. The researchers reported that the objective response rate ratio of SB8 and bevacizumab appeared equivalent, with comparable safety, pharmacokinetics and immunogenicity as a treatment of patients with metastatic or recurrent nonsquamous non-small cell lung cancer.

CN | HK | MO | TW | Bio-Thera Solutions and BeiGene announce executed agreement

August 24, 2020

Bio-Thera Solutions and BeiGene announce they have executed a license / distribution and supply agreement for BAT1706 (proposed bevacizumab biosimilar). Subject to approval by Bio-Thera’s shareholders in September, the agreement grants BeiGene the right to develop, manufacture and commercialise BAT1706 in mainland China, Hong Kong, Macau and Taiwan in return for milestone payments totalling US$165M, and tiered double-digit royalties on future net product sales.

AU | Pfizer application to PBS recommended

August 21, 2020

Pfizer’s application to PBS list its biosimilar bevacizumab (Zirabev®) under the same conditions as Avastin® was recommended.

EU | Samsung Bioepis announces EC has granted marketing authorisation for Aybintio®

August 20, 2020

Samsung Bioepis announces that the EC has granted marketing authorisation for Aybintio®, biosimilar bevacizumab (Avastin®) with a full indication set. EMA accepted Samsung’s application on 19 July 2019, and CHMP positive opinion was granted on 26 June 2020. This is Samsung’s 5th approved EU biosimilar, and the 3rd approved biosimilar to bevacizumab (following the approval of Amgen/Allergan’s Mvasti® in January 2018 and Pfizer’s Zirabev® in December 2018). Centus Biotherapeutics’ application for Equidacent® follows Samsung’s closely, having received CHMP positive opinion in July 2020.

EU | The CHMP recommends marketing authorisation for Equidacent®

July 23, 2020

The CHMP adopts a positive opinion recommending the granting of marketing authorisation for Centus Biotherapeutics’ Equidacent® (biosimilar bevacizumab) for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer and carcinoma of the cervix.

IN | Cadila Pharma announces launch of Bevaro® in India

July 22, 2020

Cadila Pharma announces it has launched Bevaro® (biosimilar bevacizumab) in India. Bevaro® s indicated for ovarian cancer, glioblastoma, colorectal cancer, breast cancer, lung cancer, cervical cancer and kidney cancer.

Celltrion reports that Ph III trials for CT-P16 are set to commence

July 15, 2020

In an interview with the Centre for Biosimilars, Celltrion’s head of marketing, Byoungseo Choi reports that Phase III trials for CT-P16 (proposed biosimilar bevacizumab) are set to commence, with EU submission planned for next year.

Outlook Therapeutics completes patient enrolment for NORSE 2 clinical trials

July 7, 2020

Outlook Therapeutics announces it has completed patient enrolment for its NORSE 2 clinical trials of Lytenava® (proposed bevacizumab biosimilar).

AU | Amgen receives Australian approval for Mvasi® as Avastin®

June 30, 2020

Amgen receives Australian approval for Mvasi® (biosimilar bevacizumab) for all indications as Avastin®.

US | Genentech files complaint against Samsung Bioepis alleging infringements

June 30, 2020

Genentech files a complaint against Samsung Bioepis in the District Court of Delaware under the BPCIA, alleging infringement of 14 patents related to SB8 (Samsung’s proposed bevacizumab biosimilar), and violation of the “patent dance” provisions.

EU | Samsung Bioepis announces CHMP’s positive apinion for Aybintio®

June 26, 2020

Samsung Bioepis announces the CHMP has adopted a positive opinion for Aybintio® (biosimilar bevacizumab).

CN | Bio-Thera Solutions announces China’s NMPA has accepted BLA for BAT1706

June 19, 2020

Bio-Thera Solutions announces China’s NMPA has accepted its BLA for BAT1706 (proposed bevacizumab biosimilar).

CN | Innovent Biologics announces China’s NMPA has approved Byvasda®

June 19, 2020

Innovent Biologics announces China’s NMPA has approved Byvasda® (bevacizumab) for the treatment of patients with advanced non-small cell lung cancer and metastatic colorectal cancer in China.

Henlius Biotech announces results of Ph III trials of HLX04

June 16, 2020

Henlius Biotech announces the results of Ph III trials of HLX04 (proposed bevacizumab biosimilar) in combination with oxaliplatin and fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Henlius reports that the study successfully met the primary endpoint.

US | Bloomberg Law reports on ongoing dispute between Genentech and Amgen

June 4, 2020

Bloomberg Law reports on the ongoing US Court of Appeals for the Federal Circuit dispute between Genentech and Amgen regarding bevacizumab. In a hearing on 3 June 2020, Genentech asked the Court to prevent Amgen selling its biosimilar bevacizumab Mvasi® to new patients, despite the trial Court refusing to prevent Amgen’s launch, and the US Court of Appeals refusing to injunct Amgen early in the appeal. Decision reserved.

Mylan announced that BLA and marketing authorisation under review by FDA and European authorities, biosimilar insulin and aflibercept projects remain on target

May 22, 2020

JD Supra reports on Mylan’s Q1 earnings call. In the call, Mylan announced that the BLA and marketing authorisation for its bevacizumab candidate is currently under review by the FDA and European authorities. Mylan also confirmed that its biosimilar insulin and aflibercept projects remain on target.

The American Journal of Medical Care publishes results of clinical trials

May 8, 2020

The American Journal of Medical Care publishes results of clinical trials of AryoGen’s BE1040V, biosimilar bevacizumab. Researchers reported the product was non-inferior to the reference product in terms of efficacy for the treatment of metastatic colorectal cancer.

US | Mylan announces FDA accepted aBLA for proposed bevacizumab biosimilar

March 6, 2020

In its 2019 Q4 earnings call, Mylan announces the FDA has accepted its aBLA for a proposed bevacizumab biosimilar. The FDA’s decision is expected on or before December 27, 2020.

Bio-Thera announces BAT1706 met endpoint in Ph III clinical trials

February 3, 2020

Bio-Thera announces BAT1706 (bevacizumab candidate) met the primary endpoint in Ph III clinical trials.

HK | TW | Mundipharma enters exclusive commercialisation agreement with Samsung

January 13, 2020

Mundipharma announces commercialisation agreement with Samsung. The agreement grants Mundipharma exclusive commercialisation rights to Samsung’s adalimumab, etanercept, trastuzumab and bevacizumab candidates in Taiwan and Hong Kong.

US | Coherus announces licensing agreement with Innovent

January 13, 2020

Coherus announces licensing agreement with Innovent for the commercialisation of Innovent’s bevacizumab candidate, with plans to file an aBLA in late 2020 or early 2021.

US | Pfizer launches bevacizumab biosimilar Zirabev®

January 7, 2020

Pfizer launches bevacizumab biosimilar Zirabev® in the US, at a 23% discount to Avastin®.

2019

CN | Qilu receives Chinese approval for bevacizumab biosimilar, Ankada®

December 17, 2019

Qilu receives Chinese approval for its bevacizumab biosimilar, Ankada®. 

AU | Pfizer receives Australian approval for bevacizumab biosimilar, Zirabev®

November 21, 2019

Pfizer receives Australian approval for bevacizumab biosimilar, Zirabev®.

US | FDA accepts BLA for proposed bevacizumab biosimilar

November 19, 2019

FDA accepts BLA for proposed bevacizumab biosimilar.

Prestige release details of upcoming Ph III clinical trials of biosimilar bevacizumab

October 12, 2019

Prestige releases details of upcoming Phase III clinical trials of biosimilar bevacizumab candidate.

Innovent releases results of Ph III clinical trials of bevacizumab biosimilar

September 19, 2019

Innovent releases results of Phase III clinical trials of bevacizumab biosimilar, reporting no statistical difference in media progression-free survival rates.

TOT Biopharm releases results of Ph I study

September 5, 2019

TOT Biopharm releases results of Phase I study of proposed BmAb biosimilar, reporting PK similarity and safety in comparison to the originator.

Henlius commences recruitment for Ph I clinical trials

August 30, 2019

Henlius commences recruitment for Phase I clinical trial of bevacizumab candidate. The trial will enrol 30 patients with solid tumours and is expected to commence in September 2019.

IN | Dr Reddy’s launces bevacizumab biosimilar Versavo® in India

August 19, 2019

Dr Reddy’s launches bevacizumab biosimiliar Versavo® in India. The product is available in 100mg and 400mg single use vials and is indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer.

EU | Samsung announces application for BmAb has been accepted for review by EMA

July 19, 2019

Samsung announces that its application for BmAb candidate SB8 has been accepted for review by the EMA.

US | Amgen launches Mvasi® in the US

July 18, 2019

Amgen launches Mvasi® in the US. Mvasi is approved for five types of cancer and was the first oncology therapeutic biosimilar approved by the FDA.

US | FDA approves Pfizer’s bevacizumab biosimilar, Zirabev®

June 28, 2019

FDA approves Pfizer’s bevacizumab biosimilar, Zirabev® for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent gliobastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Innovent presents results of efficacy and safety study

June 3, 2019

Innovent presents results of efficacy and safety study of BmAb biosimilar at the Annual Meeting of the American Society of Clinical Oncology (ASCO).

US | Genentech moves to dismiss Pfizer’s counter-claims

May 20, 2019

Genentech moves to dismiss Pfizer’s counter-claims, claiming that BPCIA legislation prevents any declaratory judgement as Pfizer did not comply with requirements during the ‘patent dance’.

US | Pfizer responds to Genentech’s complaint

April 29, 2019

Pfizer responds to Genentech’s complaint, seeking declaratory judgement of invalidity and noninfringement of all of the patents in Genentech’s complaint.

US | Genentech files complaint against Pfizer

April 5, 2019

Genentech files complaint against Pfizer in the District Court of Delaware alleging infringement of 22 patents and requesting a declaratory judgment of infringement of several of these patents.

EU | Pfizer announces EU approval for Zirabev®

February 19, 2019

Pfizer announces EU approval for Zirabev®, biosimilar BmAb.

US | Bio-Thera announces partnership with Cipla

January 14, 2019

Bio-Thera announces partnership with Cipla to commercialise BmAb candidate in emerging markets.

2018

EU | EMA Committee for Medical Products for Human Use recommends approval of Pfizer’s

December 14, 2018

The EMA’s Committee for Medicinal Products for Human Use recommends approval of Pfizer’s BmAb biosimilar Zirabev®.  This is Pfizer’s second oncology biosimilar to receive positive EMA opinion this year.

Innovent announces BmAb met endpoints in Ph III trials

December 13, 2018

Innovent announces BmAb candidate met pre-defined endpoints in Phase III trials.

CN | BmAb biosimilar approved by China’s NMPA for clinical development

October 15, 2018

BmAb biosimilar approved by China’s National Medical Products Administration for clinical development for Non-Small Cell Lung Cancer and hepatocellular carcinoma.

CN | NMPS approve Ph I and Ph III Clinical Trials for BmAb

October 15, 2018

BmAb biosimilar approved for Phase I and Phase III Clinical Trials by NMPA. 

US | FDA announces approval of Amgen’s Mvasi®

September 14, 2018

FDA announces approval of Amgen’s Mvasi®, the first BmAb biosimilar to gain approval in the US

Celltrion set to commence Ph III Clinical Trials for BmAb

August 10, 2018

Celltrion set to commence Phase III Clinical Trials for BmAb biosimilar in 150 sites across Europe, Asia and South America.

US | Amneal announces it has entered into a licensing agreement with mAbxience for it’s US bevacizumab

May 7, 2018

Amneal announces it has entered into a licensing agreement with mAbxience for its US biosimilar bevacizumab.  See subsequent mAbxience announcement here.

EU | Amgen and Allergen announce first EU approval of bevacizumab

January 18, 2018

Amgen and Allergan announce the first EU approval of biosimilar bevacizumab, to be marketed as Mvasti®.  Their application was filed with EMEA on 2 Dec 2016

2017

IN | Biocon/Mylan launches Krabeva® (bevacizumab) in India

November 23, 2017

Biocon launches Krabeva®, biosimilar bevacizumab, in India. Read more

EU | Amgen/Allergan announce EMA’s CHMP has adopted a positive opinion for ABP215 (bevacizumab)

November 10, 2017

Amgen/Allergan announce the EMA’s CHMP has adopted a positive opinion for ABP 215, biosimilar to Avastin® (bevacizumab) for the same indications as the originator. Read more

US | Genentech files further suit against Amgen (District of Delaware)

October 23, 2017

Genentech files a further suit under seal (District of Delaware) against Amgen, the third litigation existing between the parties relating to Amgen’s Mvasti® (biosimilar bevacizumab). The 25 patents at issue in this suit are the 24 patents included in the first Genentech suit and US patent 7,297,334. Read more

EU | Amgen withdraws EU application for Kyomarc® (bevacizumab)

October 17, 2017

Amgen withdraws EU application for Kyomarc® (biosimilar bevacizumab), for “marketing reasons”, but will continue with existing application for Mvasti®.  Read more

US | Amgen files suit (Central District of California) same day Genetech commences suit (District of Delaware)

October 9, 2017

Amgen files suit (Central District of California) seeking DJ that 27 patents are invalid/unenforceable/not infringed by Amgen’s biosimilar bevacizumab Mvasti®. Read more.  On the same day, Genentech commenced suit in District of Delaware against Amgen relating to Mvasti®, alleging infringement of 24 patents and non compliance with the BPCIA disclosure requirements. Read more

US | Amgen/Allergan’s bevacizumab Mvasti® approved in the US

September 14, 2017

Amgen/Allergan’s bevacizumab biosimilar (Mvasti®) (bevacizumab-awwb) approved in the US for colorectal, lung, brain, kidney and cervical cancer.  Read more 

Celltrion to commence PH I clinical trials for bevacizumab in South Korea

July 17, 2017

Celltrion to commence ph 1 clinical trials for biosimilar bevacizumab in South Korea. Read more

US | Amgen/Allergan bevacizumab recommended for approval by FDA ODAC

July 13, 2017

Amgen/Allergan’s biosimilar becvacizumab recommended for approval by FDA ODAC. Read more 

US | Amgen BmAb before FDA Oncology Drugs Advisory Committee

July 13, 2017

Amgen’s biosimilar BmAb goes before the FDA Oncology Drugs Advisory Committee in the morning session on 13 July 2017. Read more

US | PTAB institutes IPR filed by Hospira against Genentech on bevacizumab patents

March 2, 2017

PTAB institutes IPR filed by Hospira against Genentech on bevacizumab patents IPR2016-01771 (Patent 7,622,115) and IPR2016-01837 (Patent 7,807,799) from requests filed 9 September 2016.

US | Judge Sleet dismissed Genentech’s suit filed 15 February 2017

March 2, 2017

Judge Sleet dismissed Genentech’s suit filed 15 Feb 17 (see below) under Fed Cir’s finding in Amgen v Sandoz.

US | Genentech sues Amgen in District Court of Delaware relating to bevacizumab

February 15, 2017

Genentech sues Amgen in District Court of Delaware alleging non compliance with BPCIA disclosure obligations in patent dance relating to bevacizumab.

2016

US | Amgen and Allergan submit BLA for ABP 215 bevacizumab

November 15, 2016

Amgen and Allergan submit BLA for ABP 215, bevacizumab biosimilar. Read more

 

BioBlast® extract From November 15, 2016 to June 23, 2022